Last reviewed · How we verify
EGFR Monoclonal antibody — Competitive Intelligence Brief
phase 2
Small molecule
Live · refreshed every 30 min
Target snapshot
EGFR Monoclonal antibody (EGFR Monoclonal antibody) — Suzhou Genhouse Bio Co., Ltd..
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| EGFR Monoclonal antibody TARGET | EGFR Monoclonal antibody | Suzhou Genhouse Bio Co., Ltd. | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- EGFR Monoclonal antibody CI watch — RSS
- EGFR Monoclonal antibody CI watch — Atom
- EGFR Monoclonal antibody CI watch — JSON
- EGFR Monoclonal antibody alone — RSS
Cite this brief
Drug Landscape (2026). EGFR Monoclonal antibody — Competitive Intelligence Brief. https://druglandscape.com/ci/egfr-monoclonal-antibody. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab